Advanced search
Publication Cover
International Journal of Hyperthermia Volume 40, 2023 - Issue 1
Submit an article Journal homepage
961
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Feasibility of the novel vascular disrupting agent C118P for facilitating high-intensity focused ultrasound ablation of uterine fibroids

Yue Lia Shanghai Key Laboratory of Molecular Imaging, Jiading District Central Hospital Affiliated Shanghai University of Medicine and Health Sciences, Shanghai, ChinaORCID Iconhttps://orcid.org/0000-0002-4703-1651View further author information
ORCID Icon,
Jinyong Zhanga Shanghai Key Laboratory of Molecular Imaging, Jiading District Central Hospital Affiliated Shanghai University of Medicine and Health Sciences, Shanghai, ChinaView further author information
,
Changlian Lua Shanghai Key Laboratory of Molecular Imaging, Jiading District Central Hospital Affiliated Shanghai University of Medicine and Health Sciences, Shanghai, ChinaView further author information
,
Mingrui Guob School of Pharmacy, Shanghai University of Medicine and Health Sciences, Shanghai, ChinaView further author information
,
Jue Zhangc College of Medical Imaging, Shanghai University of Medicine and Health Sciences, Shanghai, ChinaView further author information
,
Gang Huanga Shanghai Key Laboratory of Molecular Imaging, Jiading District Central Hospital Affiliated Shanghai University of Medicine and Health Sciences, Shanghai, ChinaCorrespondence[email protected]
View further author information
,
Yicheng Nid Department of Imaging & Pathology, Biomedical Sciences Group, Leuven, BelgiumCorrespondence[email protected]
View further author information
&
Yini Chene Department of Ultrasound in Medicine, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicinel, Shanghai, China;f Shanghai Institute of Ultrasound in Medicine, Shanghai, ChinaCorrespondence[email protected]
View further author information
 show all
Article: 2185576 | Received 19 Sep 2022, Accepted 23 Feb 2023, Published online: 13 Mar 2023

References

  • Bachu VS, Kedda J, Suk I, et al. High-intensity focused ultrasound: a review of mechanisms and clinical applications. Ann Biomed Eng. 2021;49(9):1975–1991.
  • Jeng CJ, Ou KY, Long CY, et al. 500 cases of high-intensity focused ultrasound (HIFU) ablated uterine fibroids and adenomyosis. Taiwan J Obstet Gynecol. 2020;59(6):865–871.
  • Dogra VS, Zhang M, Bhatt S. High-intensity focused ultrasound (HIFU) therapy applications. Ultrasound Clin. 2009;4(3):307–321.
  • Lozinski T, Filipowska J, Krol P, et al. Oxytocin administration in high-intensity focused ultrasound treatment of myomata. Biomed Res Int. 2018;2018:7518026.
  • Łoziński T, Ludwin A, Filipowska J, et al. Oxytocin and misoprostol with diclofenac in the preparation for magnetic resonance-guided high-intensity ultrasound treatment of symptomatic uterine fibroids: a prospective cohort study. Ultrasound Med Biol. 2021;47(6):1573–1585.
  • Chen HM, Zhang XC, Cao HX, et al. Application value of pituitrin in the treatment of uterine fibroids with high intensity focused ultrasound. Chin J Fam Plann Gynecotokol. 2014;7:46–48.
  • Lang BHH, Woo YC, Chiu KW. Evaluation of pain during high-intensity focused ultrasound ablation of benign thyroid nodules. Eur Radiol. 2018;28(6):2620–2627.
  • Serrone J, Kocaeli H, Douglas Mast T, et al. The potential applications of high-intensity focused ultrasound (HIFU) in vascular neurosurgery. J Clin Neurosci. 2012;19(2):214–221.
  • Smolarczyk R, Czapla J, Jarosz-Biej M, et al. Vascular disrupting agents in cancer therapy. Eur J Pharmacol. 2021;891(891):173692.
  • Prise VE, Honess DJ, Stratford MR, et al. The vascular response of tumor and normal tissues in the rat to the vascular targeting agent, combretastatin A-4-phosphate, at clinically relevant doses. Int J Oncol. 2002;21(4):717–726.
  • Gaya AM, Rustin GJ. Vascular disrupting agents: a new class of drug in cancer therapy. Clin Oncol (R Coll Radiol). 2005;17(4):277–290.
  • Zhang C, Zhang X, Wang G, et al. Preclinical pharmacokinetics of C118P, a novel prodrug of microtubules inhibitor and its metabolite C118 in mice, rats, and dogs. Molecules. 2018;23(11):2883.
  • Yang M, Su Y, Wang Z, et al. C118P, a novel microtubule inhibitor with anti-angiogenic and vascular disrupting activities, exerts anti-tumor effects against hepatocellular carcinoma. Biochem Pharmacol. 2021;190:114641.
  • He J, Liu C, Li T, et al. Pictorial imaging-histopathology correlation in a rabbit with hepatic VX2 tumor treated by transarterial vascular disrupting agent administration. Int J Med Sci. 2020;17(15):2269–2275.
  • Li M, Hung A, Yang AWH. Guizhi fuling wan for uterine fibroids: a systematic review of in vivo studies. J Ethnopharmacol. 2019;245:112177.
  • Mozzachio K, Moore AB, Kissling GE, et al. Immunoexpression of steroid hormone receptors and proliferation markers in uterine leiomyoma and normal myometrial tissues from the miniature pig, Sus scrofa. Toxicol Pathol. 2016;44(3):450–457.
  • Cook AL, Rogers TD, Sowers M. Spontaneous uterine leiomyosarcoma in a rhesus macaque. Contemp Top Lab Anim Sci. 2004;43(1):47–49.
  • Galanakis N, Maris TG, Kontopodis N, et al. Perfusion imaging techniques in lower extremity peripheral arterial disease. Br J Radiol. 2022;95(1135):20211203.
  • Anderson HL, Yap JT, Miller MP, et al. Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate. J Clin Oncol. 2003;21(15):2823–2830.
  • Heeman W, Steenbergen W, van Dam G, et al. Clinical applications of laser speckle contrast imaging: a review. J Biomed Opt. 2019;24(8):1–11.
  • Balki M, Erik-Soussi M, Ramachandran N, et al. The contractile effects of oxytocin, ergonovine, and carboprost and their combinations: an in vitro study on human myometrial strips. Anesth Analg. 2015;120(5):1074–1084.
  • Cooney MM, Radivoyevitch T, Dowlati A, et al. Cardiovascular safety profile of combretastatin a4 phosphate in a single-dose phase I study in patients with advanced cancer. Clin Cancer Res. 2004;10(1 Pt 1):96–100.
  • Gill JH, Rockley KL, De Santis C, et al. Vascular disrupting agents in cancer treatment: cardiovascular toxicity and implications for co-administration with other cancer chemotherapeutics. Pharmacol Ther. 2019;202:18–31.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.